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LONG TERM SURVIVAL AS A FUNCTION OF AIRWAY
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BASED RECORD LINKAGE STUDY IN A LARGE UK
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OBJECTIVE: COPD increases morbidity and decreases life
expectancy. Airway obstruction as measured by the forced expi-
ratory volume in one second (FEV1) is used most commonly to
measure the extent of airways obstruction but the marginal
impact of FEV1 in decreasing survival is unclear. METHODS:
This was a retrospective record linkage study using data from a
region of Wales, UK, with a population of around 425,000
people. Data were probability matched from a number of data
sources: hospital utilisation data from local hospitals, lung func-
tion data from the Respiratory Medicine Department and mor-
tality data from the Ofﬁce of National Statistics. Individual data
sources were available spanning a period of 14 years to the
present. Survival was characterised from the ﬁrst recorded FEV1
measurement. Multivariate analysis techniques were used to
standardise for potentially confounding factors such as age, sex,
morbidity, BMI and smoking status. RESULTS: Among 33,357
subjects with data describing their FEV1 status, we identiﬁed
2,326 patients with COPD. Mean and median (SD and IQR)
FEV1 values at ﬁrst measurement were 1.04 litres and 0.89 litres
(0.64 and 1.15–2.62), respectively. Mean survival at one year
and at ﬁve years was 95.5% and 74.7%, respectively. In uni-
variate analysis by FEV1 quartile (1st quartile was the lowest
FEV1 value) survival at ﬁve years was 71.2%, 82.9%, 80.4%
and 85.0%. After standardisation for age, sex, morbidity,
smoking status and BMI using a Cox’s model, the hazard ratios
for the 1st, 2nd and 3rd quartile by comparison to the 4th were
2.3, 1.7 and 1.4, respectively. CONCLUSION: Airways obstruc-
tion (FEV1) was an important determinant of survival in COPD
following standardisation for other potentially confounding
factors.
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AN EVALUATION OF THE ASSOCIATION BETWEEN HEALTH
CARE UTILIAZATION AND USE OF SALMETEROL AMONG
SUBJECTS WITH ASTHMA
Wang MT, Malone DC, Skrepnek GH
University of Arizona,Tucson, AZ, USA
OBJECTIVE: Evaluate whether use of salmeterol increases the
risk in an asthma-related hospitalization or emergency care.
METHODS: Data for this study were extracted from the
MEDSTAT pharmacy and medical claims databases between
January 1, 2000 and December 31, 2001. A nested case-control
study design was employed to evaluate the associations of inter-
est. A cohort representing asthma patients was identiﬁed in
2000. The hospitalized cases were then identiﬁed as those with
the ﬁrst-time asthma-related hospitalization in 2001, and
matched to select controls from the study cohort by age (±5 years
of age), sex, and number of ambulatory visits for asthma (5 :1
control to case ratio). A similar selection process was used for
the asthma-related emergency department (ED) visit outcome.
The use of salmeterol was evaluated during the one-year period
before an index date for both cases and controls. Conditional
multiple logistic regressions were used to model the association
of interest. RESULTS: A total of 35,312 subjects were eligible to
be the study cohort. In addition, 284 and 640 subjects were iden-
tiﬁed as the hospitalized and ED cases, respectively. Current use
of salmeterol was associated with a 48 percent decrease in the
risk of an asthma-related hospitalization (OR = 0.52; 95% CI =
0.30 to 0.90) and a 30 percent reduction in the risk of an asthma-
related ED visit (OR = 0.697; p = 0.048). The protective effect
of salmeterol did not exist for those with recent or past use of
salmeterol. Conversely, use of seven or more canisters of salme-
terol had a decreased risk in the outcomes of interest (hospital-
ization: OR = 0.45; p < 0.001; ED visit: OR = 0.49; p < 0.001).
CONCLUSIONS: Salmeterol decreases the risk of health care
utilization if salmeterol is currently used or salmeterol is used for
seven or more canisters during a one-year period.
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OBJECTIVE: To estimate the total medical costs per patient and
cost per patient cured for AZ-ER 2g single dose compared with
levoﬂoxacin 750mg for 5 days for the outpatient treatment of
mild to moderate CAP from a managed care perspective.
METHODS: A cost-effectiveness model was developed to cal-
culate the total medical costs in the ﬁrst 30 days following initial
outpatient treatment of CAP. Costs included those of initial
medical management and antibiotic therapy, treatment of
adverse events and second-line treatment, including hospitaliza-
tion. Resource use was based on the American Thoracic Society
guidelines, and unit costs were assigned based on average
Medicare RBRVS and DRG reimbursement for physician visits
and hospitalizations and Wholesale Acquisition Costs for med-
ications. Likelihood of cure and adverse events were obtained
from clinical trial data comparing AZ-ER to levoﬂoxacin. To
investigate the effect of compliance on predicted healthcare costs,
cure rates were adjusted by modeling the effects of non-compli-
ance with therapy on retreatment rates. The base case prevalence
of compliance (70%) was obtained from published sources. Sen-
sitivity analyses were conducted to determine the impact of mul-
tiple variables on outcome measures. RESULTS: Average cost per
patient was $341 in the AZ-ER group and $458 in the lev-
oﬂoxacin group. Average total cost per patient cured was $375
in the AZ-ER group and $561 in the levoﬂoxacin group. The
incremental cost-effectiveness ratio indicated dominance for AZ-
ER, having both better outcomes and a lower total cost. Com-
pliance with levoﬂoxacin and cost of levoﬂoxacin were factors
having greatest impact on cost. However, AZ-ER remained the
dominant therapy compared with levoﬂoxacin at up to 94% pre-
dicted compliance with levoﬂoxacin. CONCLUSION: Use of
AZ-ER may result in lower medical costs per person than lev-
oﬂoxacin. As non-compliance with levoﬂoxacin increases, the
difference in predicted total costs per patient between AZ-ER
and levoﬂoxacin increases.
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